NO329668B1 - Kinolin- og isokinolinderivater, farmasoytiske preparater som inneholder minst en slik forbindelse, fremgangsmate for frmstilling av forbindelsene og anvendelse derav for fremstilling av farmasoytiske midler - Google Patents
Kinolin- og isokinolinderivater, farmasoytiske preparater som inneholder minst en slik forbindelse, fremgangsmate for frmstilling av forbindelsene og anvendelse derav for fremstilling av farmasoytiske midler Download PDFInfo
- Publication number
- NO329668B1 NO329668B1 NO20044731A NO20044731A NO329668B1 NO 329668 B1 NO329668 B1 NO 329668B1 NO 20044731 A NO20044731 A NO 20044731A NO 20044731 A NO20044731 A NO 20044731A NO 329668 B1 NO329668 B1 NO 329668B1
- Authority
- NO
- Norway
- Prior art keywords
- group
- methyl
- mmol
- alkyl
- ethyl acetate
- Prior art date
Links
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 title claims abstract description 14
- 125000002183 isoquinolinyl group Chemical class C1(=NC=CC2=CC=CC=C12)* 0.000 title claims abstract description 9
- 150000001875 compounds Chemical class 0.000 title claims description 106
- 239000008177 pharmaceutical agent Substances 0.000 title claims description 6
- 238000000034 method Methods 0.000 title abstract description 41
- 230000008569 process Effects 0.000 title abstract description 31
- 238000002360 preparation method Methods 0.000 title abstract description 12
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 claims description 81
- -1 alkyl metal compound Chemical class 0.000 claims description 60
- 229910052739 hydrogen Inorganic materials 0.000 claims description 28
- 239000001257 hydrogen Substances 0.000 claims description 27
- 238000006243 chemical reaction Methods 0.000 claims description 23
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 20
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims description 19
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 19
- 150000003254 radicals Chemical group 0.000 claims description 19
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 18
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 15
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 14
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 13
- 125000004432 carbon atom Chemical group C* 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 12
- 229910052736 halogen Inorganic materials 0.000 claims description 11
- 150000002367 halogens Chemical class 0.000 claims description 11
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical class C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 claims description 10
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 10
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 9
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 9
- 125000003118 aryl group Chemical group 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 8
- 150000002537 isoquinolines Chemical class 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 150000004716 alpha keto acids Chemical class 0.000 claims description 7
- 150000001412 amines Chemical class 0.000 claims description 7
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 7
- 150000001721 carbon Chemical group 0.000 claims description 7
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- 150000002148 esters Chemical class 0.000 claims description 7
- 150000002431 hydrogen Chemical class 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 6
- 239000003054 catalyst Substances 0.000 claims description 5
- 239000003153 chemical reaction reagent Substances 0.000 claims description 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 5
- 230000002829 reductive effect Effects 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 125000006833 (C1-C5) alkylene group Chemical group 0.000 claims description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical group O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 3
- 150000005840 aryl radicals Chemical class 0.000 claims description 3
- 238000006555 catalytic reaction Methods 0.000 claims description 3
- 230000008878 coupling Effects 0.000 claims description 3
- 238000010168 coupling process Methods 0.000 claims description 3
- 238000005859 coupling reaction Methods 0.000 claims description 3
- 125000005843 halogen group Chemical group 0.000 claims description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 150000004799 α-ketoamides Chemical class 0.000 claims description 3
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 claims description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 claims description 2
- 125000002252 acyl group Chemical group 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 claims description 2
- 238000005815 base catalysis Methods 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000007327 hydrogenolysis reaction Methods 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 239000012038 nucleophile Substances 0.000 claims description 2
- 238000006268 reductive amination reaction Methods 0.000 claims description 2
- 230000007704 transition Effects 0.000 claims description 2
- 229910052723 transition metal Inorganic materials 0.000 claims description 2
- 150000003624 transition metals Chemical class 0.000 claims description 2
- 150000003248 quinolines Chemical class 0.000 claims 6
- 238000007796 conventional method Methods 0.000 claims 2
- 150000003377 silicon compounds Chemical class 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 abstract description 4
- 239000003112 inhibitor Substances 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 369
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 140
- 239000000243 solution Substances 0.000 description 133
- 239000000741 silica gel Substances 0.000 description 127
- 229910002027 silica gel Inorganic materials 0.000 description 127
- 239000000047 product Substances 0.000 description 122
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 121
- 238000005160 1H NMR spectroscopy Methods 0.000 description 115
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 97
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 94
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 90
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 87
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 84
- 238000004587 chromatography analysis Methods 0.000 description 80
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 76
- 238000001704 evaporation Methods 0.000 description 75
- 230000008020 evaporation Effects 0.000 description 73
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 72
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 64
- JYVLIDXNZAXMDK-UHFFFAOYSA-N pentan-2-ol Chemical compound CCCC(C)O JYVLIDXNZAXMDK-UHFFFAOYSA-N 0.000 description 64
- 239000002904 solvent Substances 0.000 description 61
- 239000011541 reaction mixture Substances 0.000 description 60
- 229910052938 sodium sulfate Inorganic materials 0.000 description 59
- 235000011152 sodium sulphate Nutrition 0.000 description 59
- 239000012074 organic phase Substances 0.000 description 57
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 48
- 238000000746 purification Methods 0.000 description 40
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 37
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 34
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 33
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 30
- 229960000583 acetic acid Drugs 0.000 description 27
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 26
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 24
- 239000000463 material Substances 0.000 description 24
- 239000003921 oil Substances 0.000 description 24
- 235000019198 oils Nutrition 0.000 description 24
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 23
- 239000012279 sodium borohydride Substances 0.000 description 23
- 229910000033 sodium borohydride Inorganic materials 0.000 description 23
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 22
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 21
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 21
- 239000012267 brine Substances 0.000 description 19
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 19
- 230000004054 inflammatory process Effects 0.000 description 18
- 239000007787 solid Substances 0.000 description 18
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 18
- 208000010668 atopic eczema Diseases 0.000 description 17
- 239000000284 extract Substances 0.000 description 17
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 16
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 16
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 16
- 230000000172 allergic effect Effects 0.000 description 16
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 16
- 238000001816 cooling Methods 0.000 description 15
- 239000012071 phase Substances 0.000 description 15
- 230000002062 proliferating effect Effects 0.000 description 15
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 14
- 238000010626 work up procedure Methods 0.000 description 14
- IDWZSGZOZKRJQF-UHFFFAOYSA-N 4-(1,3-benzodioxol-4-yl)-2-hydroxy-4-methyl-n-quinolin-5-yl-2-(trifluoromethyl)pentanamide Chemical compound C=1C=CC2=NC=CC=C2C=1NC(=O)C(O)(C(F)(F)F)CC(C)(C)C1=CC=CC2=C1OCO2 IDWZSGZOZKRJQF-UHFFFAOYSA-N 0.000 description 13
- 201000010099 disease Diseases 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 12
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 12
- WRFLLCIDQDAHGU-UHFFFAOYSA-N 4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-(trifluoromethyl)pentanal Chemical compound COC1=CC=C(F)C=C1C(C)(C)CC(O)(C=O)C(F)(F)F WRFLLCIDQDAHGU-UHFFFAOYSA-N 0.000 description 11
- 239000007832 Na2SO4 Substances 0.000 description 11
- 239000008346 aqueous phase Substances 0.000 description 11
- 238000004440 column chromatography Methods 0.000 description 11
- 239000000706 filtrate Substances 0.000 description 11
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 10
- 239000012298 atmosphere Substances 0.000 description 10
- MSCVLAFLUUPHBK-UHFFFAOYSA-N methyl 5-aminoquinoline-2-carboxylate Chemical compound NC1=CC=CC2=NC(C(=O)OC)=CC=C21 MSCVLAFLUUPHBK-UHFFFAOYSA-N 0.000 description 10
- HGBOYTHUEUWSSQ-UHFFFAOYSA-N pentanal Chemical compound CCCCC=O HGBOYTHUEUWSSQ-UHFFFAOYSA-N 0.000 description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- ZAPDYOPHULUPJK-UHFFFAOYSA-N 1,1,1-trifluorohexan-3-ol Chemical compound CCCC(O)CC(F)(F)F ZAPDYOPHULUPJK-UHFFFAOYSA-N 0.000 description 8
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 8
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 8
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 8
- 150000002009 diols Chemical class 0.000 description 8
- 238000001914 filtration Methods 0.000 description 8
- 238000000524 positive electrospray ionisation mass spectrometry Methods 0.000 description 8
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 8
- VNWUDLTYIICXJQ-UHFFFAOYSA-N 4-(1,3-benzodioxol-4-yl)-4-methyl-2-oxo-n-quinolin-5-ylpentanamide Chemical compound C=1C=CC2=NC=CC=C2C=1NC(=O)C(=O)CC(C)(C)C1=CC=CC2=C1OCO2 VNWUDLTYIICXJQ-UHFFFAOYSA-N 0.000 description 7
- 239000012230 colorless oil Substances 0.000 description 7
- 239000012043 crude product Substances 0.000 description 7
- USLKCMBGQFYUFI-UHFFFAOYSA-N dichloromethane;tribromoborane Chemical compound ClCCl.BrB(Br)Br USLKCMBGQFYUFI-UHFFFAOYSA-N 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000003862 glucocorticoid Substances 0.000 description 7
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 7
- XMIAFAKRAAMSGX-UHFFFAOYSA-N quinolin-5-amine Chemical compound C1=CC=C2C(N)=CC=CC2=N1 XMIAFAKRAAMSGX-UHFFFAOYSA-N 0.000 description 7
- 229920006395 saturated elastomer Polymers 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- UNSLQFMTPYHZDA-UHFFFAOYSA-N 2-methylquinolin-5-amine Chemical compound NC1=CC=CC2=NC(C)=CC=C21 UNSLQFMTPYHZDA-UHFFFAOYSA-N 0.000 description 6
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical class [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 6
- 229910021529 ammonia Inorganic materials 0.000 description 6
- 239000005457 ice water Substances 0.000 description 6
- 239000012280 lithium aluminium hydride Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 239000010936 titanium Substances 0.000 description 6
- 229910052719 titanium Inorganic materials 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 102000016540 Tyrosine aminotransferases Human genes 0.000 description 5
- 108010042606 Tyrosine transaminase Proteins 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 5
- 229910000024 caesium carbonate Inorganic materials 0.000 description 5
- 239000002274 desiccant Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 239000012362 glacial acetic acid Substances 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 5
- 229940037128 systemic glucocorticoids Drugs 0.000 description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 5
- IICVTJMDHNPPOP-UHFFFAOYSA-N 2-chloro-5-nitroquinoline Chemical compound ClC1=CC=C2C([N+](=O)[O-])=CC=CC2=N1 IICVTJMDHNPPOP-UHFFFAOYSA-N 0.000 description 4
- JIMKZMITINERBL-UHFFFAOYSA-N 4-(4-chlorophenyl)-4-methyl-2-(trifluoromethyl)pentane-1,2-diol Chemical compound OCC(O)(C(F)(F)F)CC(C)(C)C1=CC=C(Cl)C=C1 JIMKZMITINERBL-UHFFFAOYSA-N 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 4
- LCGISIDBXHGCDW-VKHMYHEASA-N L-glutamine amide Chemical compound NC(=O)[C@@H](N)CCC(N)=O LCGISIDBXHGCDW-VKHMYHEASA-N 0.000 description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 4
- UZBQIPPOMKBLAS-UHFFFAOYSA-N diethylazanide Chemical compound CC[N-]CC UZBQIPPOMKBLAS-UHFFFAOYSA-N 0.000 description 4
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- VDBNYAPERZTOOF-UHFFFAOYSA-N isoquinolin-1(2H)-one Chemical compound C1=CC=C2C(=O)NC=CC2=C1 VDBNYAPERZTOOF-UHFFFAOYSA-N 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- CILJSZLWPHTUIP-UHFFFAOYSA-N methyl quinoline-2-carboxylate Chemical compound C1=CC=CC2=NC(C(=O)OC)=CC=C21 CILJSZLWPHTUIP-UHFFFAOYSA-N 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- AEABQBMUYZBBCW-UHFFFAOYSA-N pentanamide Chemical compound CC[CH]CC(N)=O AEABQBMUYZBBCW-UHFFFAOYSA-N 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 239000004323 potassium nitrate Substances 0.000 description 4
- 235000010333 potassium nitrate Nutrition 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- LOAUVZALPPNFOQ-UHFFFAOYSA-N quinaldic acid Chemical compound C1=CC=CC2=NC(C(=O)O)=CC=C21 LOAUVZALPPNFOQ-UHFFFAOYSA-N 0.000 description 4
- 238000001953 recrystallisation Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 229910000104 sodium hydride Inorganic materials 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 4
- MWKJTNBSKNUMFN-UHFFFAOYSA-N trifluoromethyltrimethylsilane Chemical compound C[Si](C)(C)C(F)(F)F MWKJTNBSKNUMFN-UHFFFAOYSA-N 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- JJPSZKIOGBRMHK-UHFFFAOYSA-N 2,6-dimethylquinoline Chemical compound N1=C(C)C=CC2=CC(C)=CC=C21 JJPSZKIOGBRMHK-UHFFFAOYSA-N 0.000 description 3
- GWSAMFZWJRKRTR-UHFFFAOYSA-N 2-(2-methyl-2-phenylpropyl)-2-(trifluoromethyl)oxirane Chemical compound C=1C=CC=CC=1C(C)(C)CC1(C(F)(F)F)CO1 GWSAMFZWJRKRTR-UHFFFAOYSA-N 0.000 description 3
- YNXOMDRPWQMDQL-UHFFFAOYSA-N 2-(4-chlorophenyl)-2-methylpropanal Chemical compound O=CC(C)(C)C1=CC=C(Cl)C=C1 YNXOMDRPWQMDQL-UHFFFAOYSA-N 0.000 description 3
- YNOKAQICKKMEPH-UHFFFAOYSA-N 2-methoxyquinolin-5-amine Chemical compound NC1=CC=CC2=NC(OC)=CC=C21 YNOKAQICKKMEPH-UHFFFAOYSA-N 0.000 description 3
- IYLAEBLVXYDTHX-UHFFFAOYSA-N 4-(1,3-benzodioxol-4-yl)-4-methyl-2-oxopentanoic acid Chemical compound OC(=O)C(=O)CC(C)(C)C1=CC=CC2=C1OCO2 IYLAEBLVXYDTHX-UHFFFAOYSA-N 0.000 description 3
- AUSYIOYSZLFMTN-UHFFFAOYSA-N 4-(4-bromo-2-methoxyphenyl)-4-methyl-2-oxo-n-quinolin-5-ylpentanamide Chemical compound COC1=CC(Br)=CC=C1C(C)(C)CC(=O)C(=O)NC1=CC=CC2=NC=CC=C12 AUSYIOYSZLFMTN-UHFFFAOYSA-N 0.000 description 3
- VMHXBMYMTJOSSG-UHFFFAOYSA-N 4-(4-chlorophenyl)-4-methyl-2-oxopentanoic acid Chemical compound OC(=O)C(=O)CC(C)(C)C1=CC=C(Cl)C=C1 VMHXBMYMTJOSSG-UHFFFAOYSA-N 0.000 description 3
- QUKYTYPIHOEBST-UHFFFAOYSA-N 4-(5-bromo-2-methoxyphenyl)-4-methyl-2-oxopentanoic acid Chemical compound COC1=CC=C(Br)C=C1C(C)(C)CC(=O)C(O)=O QUKYTYPIHOEBST-UHFFFAOYSA-N 0.000 description 3
- SAGPYTVSLBKOTA-UHFFFAOYSA-N 4-(7-bromo-1,3-benzodioxol-4-yl)-4-methyl-2-(trifluoromethyl)pentane-1,2-diol Chemical compound OCC(O)(C(F)(F)F)CC(C)(C)C1=CC=C(Br)C2=C1OCO2 SAGPYTVSLBKOTA-UHFFFAOYSA-N 0.000 description 3
- FHMOSFRBJQMZKU-UHFFFAOYSA-N 4-(7-bromo-1,3-benzodioxol-4-yl)-4-methyl-2-oxopentanoic acid Chemical compound OC(=O)C(=O)CC(C)(C)C1=CC=C(Br)C2=C1OCO2 FHMOSFRBJQMZKU-UHFFFAOYSA-N 0.000 description 3
- 239000001142 4-methyl-2-oxopentanoic acid Substances 0.000 description 3
- 206010002199 Anaphylactic shock Diseases 0.000 description 3
- 102100032187 Androgen receptor Human genes 0.000 description 3
- 206010010356 Congenital anomaly Diseases 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 239000005909 Kieselgur Substances 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 3
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 3
- 208000003455 anaphylaxis Diseases 0.000 description 3
- 108010080146 androgen receptors Proteins 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940117173 croton oil Drugs 0.000 description 3
- ZOVCJWPFNSHMKT-UHFFFAOYSA-N ethyl 2-trimethylsilyloxyprop-2-enoate Chemical compound CCOC(=O)C(=C)O[Si](C)(C)C ZOVCJWPFNSHMKT-UHFFFAOYSA-N 0.000 description 3
- LKAQUVDGPXTMDG-UHFFFAOYSA-N ethyl 4-(5-bromo-2-methoxyphenyl)-4-methyl-2-oxopentanoate Chemical compound CCOC(=O)C(=O)CC(C)(C)C1=CC(Br)=CC=C1OC LKAQUVDGPXTMDG-UHFFFAOYSA-N 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- OSILBMSORKFRTB-UHFFFAOYSA-N isoquinolin-1-amine Chemical compound C1=CC=C2C(N)=NC=CC2=C1 OSILBMSORKFRTB-UHFFFAOYSA-N 0.000 description 3
- KRPFJCUXHWEVMS-UHFFFAOYSA-N methyl 1,3-benzodioxole-4-carboxylate Chemical compound COC(=O)C1=CC=CC2=C1OCO2 KRPFJCUXHWEVMS-UHFFFAOYSA-N 0.000 description 3
- MGJXBDMLVWIYOQ-UHFFFAOYSA-N methylazanide Chemical compound [NH-]C MGJXBDMLVWIYOQ-UHFFFAOYSA-N 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 102000003998 progesterone receptors Human genes 0.000 description 3
- 108090000468 progesterone receptors Proteins 0.000 description 3
- ZEXKKIXCRDTKBF-UHFFFAOYSA-N quinoline-2-carboxamide Chemical compound C1=CC=CC2=NC(C(=O)N)=CC=C21 ZEXKKIXCRDTKBF-UHFFFAOYSA-N 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 201000000306 sarcoidosis Diseases 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 102000005969 steroid hormone receptors Human genes 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- FCYBQEKYUOPTJU-UHFFFAOYSA-N (5-aminoquinolin-2-yl)methyl acetate Chemical compound NC1=CC=CC2=NC(COC(=O)C)=CC=C21 FCYBQEKYUOPTJU-UHFFFAOYSA-N 0.000 description 2
- RPXHSIORXKDLOL-UHFFFAOYSA-N (5-nitroquinolin-2-yl)methanol Chemical compound [O-][N+](=O)C1=CC=CC2=NC(CO)=CC=C21 RPXHSIORXKDLOL-UHFFFAOYSA-N 0.000 description 2
- PGRKQGKFSIJVEC-UHFFFAOYSA-N (5-nitroquinolin-2-yl)methyl acetate Chemical compound [O-][N+](=O)C1=CC=CC2=NC(COC(=O)C)=CC=C21 PGRKQGKFSIJVEC-UHFFFAOYSA-N 0.000 description 2
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 2
- IOGQZPMTFAHBMM-UHFFFAOYSA-N 1-[3-(methylamino)-5-nitroquinolin-2-yl]ethanone Chemical compound C1=CC=C2N=C(C(C)=O)C(NC)=CC2=C1[N+]([O-])=O IOGQZPMTFAHBMM-UHFFFAOYSA-N 0.000 description 2
- YIWWNCVRZUTBOF-UHFFFAOYSA-N 1-[5-amino-3-(methylamino)quinolin-2-yl]ethanone Chemical compound C1=CC=C2N=C(C(C)=O)C(NC)=CC2=C1N YIWWNCVRZUTBOF-UHFFFAOYSA-N 0.000 description 2
- YUKILTJWFRTXGB-UHFFFAOYSA-N 1-chloro-3-methoxybenzene Chemical compound COC1=CC=CC(Cl)=C1 YUKILTJWFRTXGB-UHFFFAOYSA-N 0.000 description 2
- JDACVGMXKJWJKK-UHFFFAOYSA-N 2,3-dihydroxy-4-nitrobenzaldehyde Chemical compound OC1=C(O)C([N+]([O-])=O)=CC=C1C=O JDACVGMXKJWJKK-UHFFFAOYSA-N 0.000 description 2
- GLDQAMYCGOIJDV-UHFFFAOYSA-N 2,3-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC(O)=C1O GLDQAMYCGOIJDV-UHFFFAOYSA-N 0.000 description 2
- SSJOWWYMHNQEMM-UHFFFAOYSA-N 2,6-dimethylquinolin-5-amine Chemical compound NC1=C(C)C=CC2=NC(C)=CC=C21 SSJOWWYMHNQEMM-UHFFFAOYSA-N 0.000 description 2
- PWTRJTSMRTULMY-UHFFFAOYSA-N 2-(5-bromo-2-methoxyphenyl)propan-2-ol Chemical compound COC1=CC=C(Br)C=C1C(C)(C)O PWTRJTSMRTULMY-UHFFFAOYSA-N 0.000 description 2
- XGJKZPKHZWPCEU-UHFFFAOYSA-N 2-(morpholin-4-ylmethyl)quinolin-5-amine Chemical compound C=1C=C2C(N)=CC=CC2=NC=1CN1CCOCC1 XGJKZPKHZWPCEU-UHFFFAOYSA-N 0.000 description 2
- UGYLLBKPGJJJAY-UHFFFAOYSA-N 2-(trifluoromethyl)quinolin-5-amine Chemical compound FC(F)(F)C1=CC=C2C(N)=CC=CC2=N1 UGYLLBKPGJJJAY-UHFFFAOYSA-N 0.000 description 2
- YZSRICFIQLVSMQ-UHFFFAOYSA-N 2-(trifluoromethyl)quinoline Chemical compound C1=CC=CC2=NC(C(F)(F)F)=CC=C21 YZSRICFIQLVSMQ-UHFFFAOYSA-N 0.000 description 2
- OMXWTMUDBIBNGY-UHFFFAOYSA-N 2-[(2-ethylquinolin-5-yl)iminomethyl]-1,1,1-trifluoro-4-(5-fluoro-2-methoxyphenyl)-4-methylpentan-2-ol Chemical compound C=1C=CC2=NC(CC)=CC=C2C=1N=CC(O)(C(F)(F)F)CC(C)(C)C1=CC(F)=CC=C1OC OMXWTMUDBIBNGY-UHFFFAOYSA-N 0.000 description 2
- UTFPDMJLYNRZKP-UHFFFAOYSA-N 2-[4-[[(2,6-dimethylquinolin-5-yl)amino]methyl]-5,5,5-trifluoro-4-hydroxy-2-methylpentan-2-yl]-4-fluorophenol Chemical compound CC=1C=CC2=NC(C)=CC=C2C=1NCC(O)(C(F)(F)F)CC(C)(C)C1=CC(F)=CC=C1O UTFPDMJLYNRZKP-UHFFFAOYSA-N 0.000 description 2
- FBPINGSGHKXIQA-UHFFFAOYSA-N 2-amino-3-(2-carboxyethylsulfanyl)propanoic acid Chemical compound OC(=O)C(N)CSCCC(O)=O FBPINGSGHKXIQA-UHFFFAOYSA-N 0.000 description 2
- OFUFXTHGZWIDDB-UHFFFAOYSA-N 2-chloroquinoline Chemical compound C1=CC=CC2=NC(Cl)=CC=C21 OFUFXTHGZWIDDB-UHFFFAOYSA-N 0.000 description 2
- JYYDVCMSWBKAIJ-UHFFFAOYSA-N 2-ethenyl-5-nitroquinoline Chemical compound C=CC1=CC=C2C([N+](=O)[O-])=CC=CC2=N1 JYYDVCMSWBKAIJ-UHFFFAOYSA-N 0.000 description 2
- NYZGSVMHIRDDAO-UHFFFAOYSA-N 2-methoxy-5-nitroquinoline Chemical compound [O-][N+](=O)C1=CC=CC2=NC(OC)=CC=C21 NYZGSVMHIRDDAO-UHFFFAOYSA-N 0.000 description 2
- XJHADKRGUJCHOO-UHFFFAOYSA-N 2-methyl-5-nitroquinoline Chemical compound [O-][N+](=O)C1=CC=CC2=NC(C)=CC=C21 XJHADKRGUJCHOO-UHFFFAOYSA-N 0.000 description 2
- HDECRAPHCDXMIJ-UHFFFAOYSA-N 2-methylbenzenesulfonyl chloride Chemical compound CC1=CC=CC=C1S(Cl)(=O)=O HDECRAPHCDXMIJ-UHFFFAOYSA-N 0.000 description 2
- WMJLDNKVDMIGHC-UHFFFAOYSA-N 4-(2-chloro-4-methoxyphenyl)-4-methyl-2-(trifluoromethyl)pentane-1,2-diol Chemical compound COC1=CC=C(C(C)(C)CC(O)(CO)C(F)(F)F)C(Cl)=C1 WMJLDNKVDMIGHC-UHFFFAOYSA-N 0.000 description 2
- OESCYAPQFSNTHU-UHFFFAOYSA-N 4-(2-chloro-5-fluorophenyl)-4-methyl-2-oxo-n-quinolin-5-ylpentanamide Chemical compound C=1C=CC2=NC=CC=C2C=1NC(=O)C(=O)CC(C)(C)C1=CC(F)=CC=C1Cl OESCYAPQFSNTHU-UHFFFAOYSA-N 0.000 description 2
- YGZZTGFUGGTXAN-UHFFFAOYSA-N 4-(4-chloro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-(trifluoromethyl)pentanal Chemical compound COC1=CC(Cl)=CC=C1C(C)(C)CC(O)(C=O)C(F)(F)F YGZZTGFUGGTXAN-UHFFFAOYSA-N 0.000 description 2
- GWYLLKSJTXXNKH-UHFFFAOYSA-N 4-(4-chloro-2-methoxyphenyl)-4-methyl-2-(trifluoromethyl)pentane-1,2-diol Chemical compound COC1=CC(Cl)=CC=C1C(C)(C)CC(O)(CO)C(F)(F)F GWYLLKSJTXXNKH-UHFFFAOYSA-N 0.000 description 2
- YMSHAISWRRFXCM-UHFFFAOYSA-N 4-(5-bromo-2-methoxyphenyl)-4-methyl-2-oxo-n-quinolin-5-ylpentanamide Chemical compound COC1=CC=C(Br)C=C1C(C)(C)CC(=O)C(=O)NC1=CC=CC2=NC=CC=C12 YMSHAISWRRFXCM-UHFFFAOYSA-N 0.000 description 2
- RDOXSPBOZWJLBI-UHFFFAOYSA-N 4-methyl-2-oxo-4-phenyl-n-quinolin-5-ylpentanamide Chemical compound C=1C=CC2=NC=CC=C2C=1NC(=O)C(=O)CC(C)(C)C1=CC=CC=C1 RDOXSPBOZWJLBI-UHFFFAOYSA-N 0.000 description 2
- JQFGKPKESVXEOM-UHFFFAOYSA-N 4-methyl-2-oxo-4-phenylpentanoic acid Chemical compound OC(=O)C(=O)CC(C)(C)C1=CC=CC=C1 JQFGKPKESVXEOM-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- RSKDHNLUQZJTGG-UHFFFAOYSA-N 5-(5-fluoro-2-methoxyphenyl)-3-hydroxy-5-methyl-3-(trifluoromethyl)hexan-2-one Chemical compound COC1=CC=C(F)C=C1C(C)(C)CC(O)(C(C)=O)C(F)(F)F RSKDHNLUQZJTGG-UHFFFAOYSA-N 0.000 description 2
- XPYDBVFMTKMAQW-UHFFFAOYSA-N 5-(5-fluoro-2-methoxyphenyl)-5-methyl-2-(2-methylquinolin-5-yl)imino-3-(trifluoromethyl)hexan-3-ol Chemical compound COC1=CC=C(F)C=C1C(C)(C)CC(O)(C(F)(F)F)C(C)=NC1=CC=CC2=NC(C)=CC=C12 XPYDBVFMTKMAQW-UHFFFAOYSA-N 0.000 description 2
- DANDEJPAZFBPAS-UHFFFAOYSA-N 5-amino-1h-quinolin-2-one Chemical compound OC1=CC=C2C(N)=CC=CC2=N1 DANDEJPAZFBPAS-UHFFFAOYSA-N 0.000 description 2
- SVASVGVAQIVSEZ-UHFFFAOYSA-N 5-amino-2H-isoquinolin-1-one Chemical compound C1=CNC(=O)C2=C1C(N)=CC=C2 SVASVGVAQIVSEZ-UHFFFAOYSA-N 0.000 description 2
- GJDINLXWCRGXHR-UHFFFAOYSA-N 5-aminoquinoline-2-carboxamide Chemical compound NC1=CC=CC2=NC(C(=O)N)=CC=C21 GJDINLXWCRGXHR-UHFFFAOYSA-N 0.000 description 2
- CMZRGZILWKLDMH-UHFFFAOYSA-N 5-nitro-1-oxidoquinolin-1-ium Chemical compound C1=CC=C2C([N+](=O)[O-])=CC=CC2=[N+]1[O-] CMZRGZILWKLDMH-UHFFFAOYSA-N 0.000 description 2
- HDLBENCEXXAUMM-UHFFFAOYSA-N 5-nitro-2-(trifluoromethyl)quinoline Chemical compound FC(F)(F)C1=CC=C2C([N+](=O)[O-])=CC=CC2=N1 HDLBENCEXXAUMM-UHFFFAOYSA-N 0.000 description 2
- GMDPUTAUKHHDCI-UHFFFAOYSA-N 5-nitro-2h-isoquinolin-1-one Chemical compound C1=CNC(=O)C2=C1C([N+](=O)[O-])=CC=C2 GMDPUTAUKHHDCI-UHFFFAOYSA-N 0.000 description 2
- KCYWNAAVPRMMLP-UHFFFAOYSA-N 5-nitroisochromen-1-one Chemical compound C1=COC(=O)C2=C1C([N+](=O)[O-])=CC=C2 KCYWNAAVPRMMLP-UHFFFAOYSA-N 0.000 description 2
- GBNFEQLBVCUBTG-UHFFFAOYSA-N 5-nitroquinolin-2-amine Chemical compound [O-][N+](=O)C1=CC=CC2=NC(N)=CC=C21 GBNFEQLBVCUBTG-UHFFFAOYSA-N 0.000 description 2
- KZSIMXFHPRWAFJ-UHFFFAOYSA-N 7-amino-1,3-benzodioxole-4-carboxylic acid Chemical compound NC1=CC=C(C(O)=O)C2=C1OCO2 KZSIMXFHPRWAFJ-UHFFFAOYSA-N 0.000 description 2
- ZJCFXKIDPHPZNA-UHFFFAOYSA-N 8-aminoquinoline-2-carboxamide Chemical compound C1=CC=C(N)C2=NC(C(=O)N)=CC=C21 ZJCFXKIDPHPZNA-UHFFFAOYSA-N 0.000 description 2
- 208000026872 Addison Disease Diseases 0.000 description 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 2
- 206010048962 Brain oedema Diseases 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 206010037423 Pulmonary oedema Diseases 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- 108010085012 Steroid Receptors Proteins 0.000 description 2
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 150000005010 aminoquinolines Chemical class 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- 208000006752 brain edema Diseases 0.000 description 2
- JPOXNPPZZKNXOV-UHFFFAOYSA-N bromochloromethane Chemical compound ClCBr JPOXNPPZZKNXOV-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000000613 ear canal Anatomy 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000003365 glass fiber Substances 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- CCERQOYLJJULMD-UHFFFAOYSA-M magnesium;carbanide;chloride Chemical compound [CH3-].[Mg+2].[Cl-] CCERQOYLJJULMD-UHFFFAOYSA-M 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- GSHAPJLBLHVQQM-UHFFFAOYSA-N n-(5-aminoquinolin-2-yl)acetamide Chemical compound NC1=CC=CC2=NC(NC(=O)C)=CC=C21 GSHAPJLBLHVQQM-UHFFFAOYSA-N 0.000 description 2
- FSQSHLHLFZKHLX-UHFFFAOYSA-N n-(5-nitroquinolin-2-yl)acetamide Chemical compound [O-][N+](=O)C1=CC=CC2=NC(NC(=O)C)=CC=C21 FSQSHLHLFZKHLX-UHFFFAOYSA-N 0.000 description 2
- MZPSQAFULOOFHW-UHFFFAOYSA-N n-[5-[[4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-(trifluoromethyl)pentyl]amino]quinolin-2-yl]acetamide Chemical compound COC1=CC=C(F)C=C1C(C)(C)CC(O)(C(F)(F)F)CNC1=CC=CC2=NC(NC(C)=O)=CC=C12 MZPSQAFULOOFHW-UHFFFAOYSA-N 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 2
- 125000004894 pentylamino group Chemical group C(CCCC)N* 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical class [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- OPFMBYIQGSJDOB-ONEGZZNKSA-N (e)-4-(dimethylamino)-1,1,1-trifluorobut-3-en-2-one Chemical compound CN(C)\C=C\C(=O)C(F)(F)F OPFMBYIQGSJDOB-ONEGZZNKSA-N 0.000 description 1
- QQSZVYBGSFNEFW-UHFFFAOYSA-N 1,1,1-trifluoro-2-[[1-(5-fluoro-2-methoxyphenyl)cyclopropyl]methyl]-3-(2-methylquinolin-5-yl)iminopropan-2-ol Chemical compound COC1=CC=C(F)C=C1C1(CC(O)(C=NC=2C3=CC=C(C)N=C3C=CC=2)C(F)(F)F)CC1 QQSZVYBGSFNEFW-UHFFFAOYSA-N 0.000 description 1
- CAJGRIPDRHYSJP-UHFFFAOYSA-N 1,1,1-trifluoro-4-(5-fluoro-2-methoxyphenyl)-2-(isoquinolin-5-yliminomethyl)-4-methylpentan-2-ol Chemical compound COC1=CC=C(F)C=C1C(C)(C)CC(O)(C(F)(F)F)C=NC1=CC=CC2=CN=CC=C12 CAJGRIPDRHYSJP-UHFFFAOYSA-N 0.000 description 1
- GXIPDOJMXCLLNI-UHFFFAOYSA-N 1,1,1-trifluoro-4-(5-fluoro-2-methoxyphenyl)-2-[(isoquinolin-1-ylamino)methyl]-4-methylpentan-2-ol Chemical compound COC1=CC=C(F)C=C1C(C)(C)CC(O)(C(F)(F)F)CNC1=NC=CC2=CC=CC=C12 GXIPDOJMXCLLNI-UHFFFAOYSA-N 0.000 description 1
- COBNRQQOJQVFCK-UHFFFAOYSA-N 1,1,1-trifluoro-4-(5-fluoro-2-methoxyphenyl)-2-[(isoquinolin-5-ylamino)methyl]-4-methylpentan-2-ol Chemical compound COC1=CC=C(F)C=C1C(C)(C)CC(O)(C(F)(F)F)CNC1=CC=CC2=CN=CC=C12 COBNRQQOJQVFCK-UHFFFAOYSA-N 0.000 description 1
- GGCFTHXEDWANQP-UHFFFAOYSA-N 1,1,1-trifluoro-4-(5-fluoro-2-methoxyphenyl)-4-methyl-2-[[[2-(morpholin-4-ylmethyl)quinolin-5-yl]amino]methyl]pentan-2-ol Chemical compound COC1=CC=C(F)C=C1C(C)(C)CC(O)(C(F)(F)F)CNC1=CC=CC2=NC(CN3CCOCC3)=CC=C12 GGCFTHXEDWANQP-UHFFFAOYSA-N 0.000 description 1
- 125000006002 1,1-difluoroethyl group Chemical group 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- QVCUKHQDEZNNOC-UHFFFAOYSA-N 1,2-diazabicyclo[2.2.2]octane Chemical compound C1CC2CCN1NC2 QVCUKHQDEZNNOC-UHFFFAOYSA-N 0.000 description 1
- NQPJDJVGBDHCAD-UHFFFAOYSA-N 1,3-diazinan-2-one Chemical compound OC1=NCCCN1 NQPJDJVGBDHCAD-UHFFFAOYSA-N 0.000 description 1
- KPZGRMZPZLOPBS-UHFFFAOYSA-N 1,3-dichloro-2,2-bis(chloromethyl)propane Chemical compound ClCC(CCl)(CCl)CCl KPZGRMZPZLOPBS-UHFFFAOYSA-N 0.000 description 1
- BNMNQUBPZZSXQU-UHFFFAOYSA-N 1,3-dioxole-4-carboxylic acid Chemical compound OC(=O)C1=COCO1 BNMNQUBPZZSXQU-UHFFFAOYSA-N 0.000 description 1
- APFBFSBZXLCCBN-UHFFFAOYSA-N 1-(5-amino-2-methyl-2h-quinolin-1-yl)ethanone Chemical compound C1=CC=C2N(C(C)=O)C(C)C=CC2=C1N APFBFSBZXLCCBN-UHFFFAOYSA-N 0.000 description 1
- KVNZFWPYCIFZPN-UHFFFAOYSA-N 1-(5-nitro-2h-quinolin-1-yl)ethane-1,2-diol Chemical compound C1=CC=C([N+]([O-])=O)C2=C1N(C(O)CO)CC=C2 KVNZFWPYCIFZPN-UHFFFAOYSA-N 0.000 description 1
- YPQAFWHSMWWPLX-UHFFFAOYSA-N 1975-50-4 Chemical compound CC1=C(C(O)=O)C=CC=C1[N+]([O-])=O YPQAFWHSMWWPLX-UHFFFAOYSA-N 0.000 description 1
- 229940082044 2,3-dihydroxybenzoic acid Drugs 0.000 description 1
- XBBNUWOUDAUOJR-UHFFFAOYSA-N 2-(1,3-benzodioxol-4-yl)propan-2-ol Chemical compound CC(C)(O)C1=CC=CC2=C1OCO2 XBBNUWOUDAUOJR-UHFFFAOYSA-N 0.000 description 1
- GQOLYABRQATDOI-UHFFFAOYSA-N 2-(4-chlorophenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)C1=CC=C(Cl)C=C1 GQOLYABRQATDOI-UHFFFAOYSA-N 0.000 description 1
- VMQCUXXWRORLDS-UHFFFAOYSA-N 2-(7-bromo-1,3-benzodioxol-4-yl)propan-2-ol Chemical compound CC(C)(O)C1=CC=C(Br)C2=C1OCO2 VMQCUXXWRORLDS-UHFFFAOYSA-N 0.000 description 1
- HVHIGTIZVSBTHW-UHFFFAOYSA-N 2-(bromomethyl)-5-nitroquinoline Chemical compound BrCC1=CC=C2C([N+](=O)[O-])=CC=CC2=N1 HVHIGTIZVSBTHW-UHFFFAOYSA-N 0.000 description 1
- RIJBHAXATUPJIY-UHFFFAOYSA-N 2-[2-(5-fluoro-2-methoxyphenyl)-2-methylpropyl]-2-(trifluoromethyl)oxirane Chemical compound COC1=CC=C(F)C=C1C(C)(C)CC1(C(F)(F)F)OC1 RIJBHAXATUPJIY-UHFFFAOYSA-N 0.000 description 1
- NATZFPUFORIUNE-UHFFFAOYSA-N 2-[4-[[(6-chloro-2-methylquinolin-5-yl)amino]methyl]-5,5,5-trifluoro-4-hydroxy-2-methylpentan-2-yl]-4-fluorophenol Chemical compound ClC=1C=CC2=NC(C)=CC=C2C=1NCC(O)(C(F)(F)F)CC(C)(C)C1=CC(F)=CC=C1O NATZFPUFORIUNE-UHFFFAOYSA-N 0.000 description 1
- ODMVRQWYRLIMQJ-UHFFFAOYSA-N 2-[4-[[(6-chloro-2-methylquinolin-5-yl)amino]methyl]-5,5,5-trifluoro-4-hydroxy-2-methylpentan-2-yl]-6-fluorophenol Chemical compound ClC=1C=CC2=NC(C)=CC=C2C=1NCC(O)(C(F)(F)F)CC(C)(C)C1=CC=CC(F)=C1O ODMVRQWYRLIMQJ-UHFFFAOYSA-N 0.000 description 1
- XYHPTZAZFYYFIP-UHFFFAOYSA-N 2-[[1-(2-chloro-5-fluorophenyl)cyclobutyl]methyl]-3,3,3-trifluoropropanal Chemical compound FC1=CC=C(Cl)C(C2(CC(C=O)C(F)(F)F)CCC2)=C1 XYHPTZAZFYYFIP-UHFFFAOYSA-N 0.000 description 1
- AJGBYJMGQNVVSA-UHFFFAOYSA-N 2-ethoxy-5-nitroquinoline Chemical compound [O-][N+](=O)C1=CC=CC2=NC(OCC)=CC=C21 AJGBYJMGQNVVSA-UHFFFAOYSA-N 0.000 description 1
- XMDSWAUTNAPYLS-UHFFFAOYSA-N 2-ethoxyquinolin-5-amine Chemical compound NC1=CC=CC2=NC(OCC)=CC=C21 XMDSWAUTNAPYLS-UHFFFAOYSA-N 0.000 description 1
- SSAGFNGDURGLIQ-UHFFFAOYSA-N 2-ethylquinolin-5-amine Chemical compound NC1=CC=CC2=NC(CC)=CC=C21 SSAGFNGDURGLIQ-UHFFFAOYSA-N 0.000 description 1
- PAQVXXZKNYZUOH-UHFFFAOYSA-N 2-hydroxy-3-methoxy-4-nitrobenzaldehyde Chemical compound COC1=C(O)C(C=O)=CC=C1[N+]([O-])=O PAQVXXZKNYZUOH-UHFFFAOYSA-N 0.000 description 1
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000004714 2-methylbutylthio group Chemical group CC(CS*)CC 0.000 description 1
- NNUVIALYVQYRJL-UHFFFAOYSA-N 3,3,3-trifluoro-2-[[1-(5-fluoro-2-methoxyphenyl)cyclopropyl]methyl]-2-hydroxypropanal Chemical compound COC1=CC=C(F)C=C1C1(CC(O)(C=O)C(F)(F)F)CC1 NNUVIALYVQYRJL-UHFFFAOYSA-N 0.000 description 1
- KIQZPUITHMEQLG-UHFFFAOYSA-N 3-[1-(2-chloro-4-fluorophenyl)cyclopropyl]-2-hydroxy-n-quinolin-5-yl-2-(trifluoromethyl)pentanamide Chemical compound C=1C=CC2=NC=CC=C2C=1NC(=O)C(O)(C(F)(F)F)C(CC)C1(C=2C(=CC(F)=CC=2)Cl)CC1 KIQZPUITHMEQLG-UHFFFAOYSA-N 0.000 description 1
- YYFLDZZDOUDZQM-UHFFFAOYSA-N 3-[1-[[4-(3-phenylquinolin-2-yl)phenyl]methyl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound O=C1NC2=CC=CC=C2N1C(CC1)CCN1CC(C=C1)=CC=C1C1=NC2=CC=CC=C2C=C1C1=CC=CC=C1 YYFLDZZDOUDZQM-UHFFFAOYSA-N 0.000 description 1
- 125000001331 3-methylbutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000004715 3-methylbutylthio group Chemical group CC(CCS*)C 0.000 description 1
- MZYWEUWEIXJBPQ-UHFFFAOYSA-N 4,4,4-trifluorobutan-2-ol Chemical compound CC(O)CC(F)(F)F MZYWEUWEIXJBPQ-UHFFFAOYSA-N 0.000 description 1
- LBZIEZSHLDFMCZ-UHFFFAOYSA-N 4-(1,3-benzodioxol-4-yl)-4-methyl-2-(trifluoromethyl)pentane-1,2-diol Chemical compound OCC(O)(C(F)(F)F)CC(C)(C)C1=CC=CC2=C1OCO2 LBZIEZSHLDFMCZ-UHFFFAOYSA-N 0.000 description 1
- VRKALVLGIAPKEY-UHFFFAOYSA-N 4-(2,5-difluorophenyl)-4-methyl-2-(trifluoromethyl)pentanal Chemical compound O=CC(C(F)(F)F)CC(C)(C)C1=CC(F)=CC=C1F VRKALVLGIAPKEY-UHFFFAOYSA-N 0.000 description 1
- GXVPENFLGGZVDA-UHFFFAOYSA-N 4-(2-chloro-5-fluorophenyl)-2-hydroxy-4-methyl-n-quinolin-5-yl-2-(trifluoromethyl)pentanamide Chemical compound C=1C=CC2=NC=CC=C2C=1NC(=O)C(O)(C(F)(F)F)CC(C)(C)C1=CC(F)=CC=C1Cl GXVPENFLGGZVDA-UHFFFAOYSA-N 0.000 description 1
- SKTZRUDGYWSNNT-UHFFFAOYSA-N 4-(2-chloro-5-fluorophenyl)-4-methyl-2-oxopentanoic acid Chemical compound OC(=O)C(=O)CC(C)(C)C1=CC(F)=CC=C1Cl SKTZRUDGYWSNNT-UHFFFAOYSA-N 0.000 description 1
- HRYPFPPWXRWYHS-UHFFFAOYSA-N 4-(2-chlorophenyl)-2-hydroxy-4-methyl-n-quinolin-5-yl-2-(trifluoromethyl)pentanamide Chemical compound C=1C=CC2=NC=CC=C2C=1NC(=O)C(O)(C(F)(F)F)CC(C)(C)C1=CC=CC=C1Cl HRYPFPPWXRWYHS-UHFFFAOYSA-N 0.000 description 1
- PDICOYPBPNVGDZ-UHFFFAOYSA-N 4-(2-chlorophenyl)-4-methyl-2-oxo-n-quinolin-5-ylpentanamide Chemical compound C=1C=CC2=NC=CC=C2C=1NC(=O)C(=O)CC(C)(C)C1=CC=CC=C1Cl PDICOYPBPNVGDZ-UHFFFAOYSA-N 0.000 description 1
- YDJFWYBMAAQERR-UHFFFAOYSA-N 4-(2-chlorophenyl)-4-methyl-2-oxopentanoic acid Chemical compound OC(=O)C(=O)CC(C)(C)C1=CC=CC=C1Cl YDJFWYBMAAQERR-UHFFFAOYSA-N 0.000 description 1
- PXLGXUSMFYDZQH-UHFFFAOYSA-N 4-(4-bromo-2-methoxyphenyl)-4-methyl-2-oxopentanoic acid Chemical compound COC1=CC(Br)=CC=C1C(C)(C)CC(=O)C(O)=O PXLGXUSMFYDZQH-UHFFFAOYSA-N 0.000 description 1
- HQJQRWCRNBMYSE-UHFFFAOYSA-N 4-(5-chloro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-(trifluoromethyl)pentanal Chemical compound COC1=CC=C(Cl)C=C1C(C)(C)CC(O)(C=O)C(F)(F)F HQJQRWCRNBMYSE-UHFFFAOYSA-N 0.000 description 1
- DTDUCWHRYUZKBH-UHFFFAOYSA-N 4-(5-fluoro-2-methoxyphenyl)-4-methyl-2-(trifluoromethyl)pentane-1,2-diol Chemical compound COC1=CC=C(F)C=C1C(C)(C)CC(O)(CO)C(F)(F)F DTDUCWHRYUZKBH-UHFFFAOYSA-N 0.000 description 1
- OUPZJSRHRVZYQJ-UHFFFAOYSA-N 4-[(5-nitroquinolin-2-yl)methyl]morpholine Chemical compound C=1C=C2C([N+](=O)[O-])=CC=CC2=NC=1CN1CCOCC1 OUPZJSRHRVZYQJ-UHFFFAOYSA-N 0.000 description 1
- IVYMIRMKXZAHRV-UHFFFAOYSA-N 4-chlorophenylacetonitrile Chemical compound ClC1=CC=C(CC#N)C=C1 IVYMIRMKXZAHRV-UHFFFAOYSA-N 0.000 description 1
- KNDOFJFSHZCKGT-UHFFFAOYSA-N 4-chloroquinoline Chemical compound C1=CC=C2C(Cl)=CC=NC2=C1 KNDOFJFSHZCKGT-UHFFFAOYSA-N 0.000 description 1
- PQVQTJSZDAQJGZ-UHFFFAOYSA-N 4-fluoro-2-[5,5,5-trifluoro-4-hydroxy-2-methyl-4-[(quinolin-8-ylamino)methyl]pentan-2-yl]phenol Chemical compound C=1C=CC2=CC=CN=C2C=1NCC(O)(C(F)(F)F)CC(C)(C)C1=CC(F)=CC=C1O PQVQTJSZDAQJGZ-UHFFFAOYSA-N 0.000 description 1
- REEPFLFXEYDSCM-UHFFFAOYSA-N 4-fluoro-2-[5,5,5-trifluoro-4-hydroxy-2-methyl-4-[[(2-methylquinolin-5-yl)amino]methyl]pentan-2-yl]phenol Chemical compound C=1C=CC2=NC(C)=CC=C2C=1NCC(O)(C(F)(F)F)CC(C)(C)C1=CC(F)=CC=C1O REEPFLFXEYDSCM-UHFFFAOYSA-N 0.000 description 1
- RHQXXYOJDUMMGR-UHFFFAOYSA-N 4-fluoro-2-[5,5,5-trifluoro-4-hydroxy-4-(isoquinolin-5-ylmethyl)-2-methylpentan-2-yl]phenol Chemical compound C=1C=CC2=CN=CC=C2C=1CC(O)(C(F)(F)F)CC(C)(C)C1=CC(F)=CC=C1O RHQXXYOJDUMMGR-UHFFFAOYSA-N 0.000 description 1
- WAZPLXZGZWWXDQ-UHFFFAOYSA-N 4-methyl-4-oxidomorpholin-4-ium;hydrate Chemical compound O.C[N+]1([O-])CCOCC1 WAZPLXZGZWWXDQ-UHFFFAOYSA-N 0.000 description 1
- GBVZSKCGAAQWCK-UHFFFAOYSA-N 4-methyl-4-phenyl-2-(trifluoromethyl)pentane-1,2-diol Chemical compound OCC(O)(C(F)(F)F)CC(C)(C)C1=CC=CC=C1 GBVZSKCGAAQWCK-UHFFFAOYSA-N 0.000 description 1
- HQQTZCPKNZVLFF-UHFFFAOYSA-N 4h-1,2-benzoxazin-3-one Chemical class C1=CC=C2ONC(=O)CC2=C1 HQQTZCPKNZVLFF-UHFFFAOYSA-N 0.000 description 1
- FJVWAVXEEBVZNI-UHFFFAOYSA-N 5-(5-fluoro-2-methoxyphenyl)-5-methyl-2-[(2-methylquinolin-5-yl)amino]-3-(trifluoromethyl)hexan-3-ol Chemical compound COC1=CC=C(F)C=C1C(C)(C)CC(O)(C(F)(F)F)C(C)NC1=CC=CC2=NC(C)=CC=C12 FJVWAVXEEBVZNI-UHFFFAOYSA-N 0.000 description 1
- AYISNUJNKVSRPL-UHFFFAOYSA-N 5-(5-fluoro-2-methoxyphenyl)-5-methyl-3-(trifluoromethyl)hexane-2,3-diol Chemical compound COC1=CC=C(F)C=C1C(C)(C)CC(O)(C(C)O)C(F)(F)F AYISNUJNKVSRPL-UHFFFAOYSA-N 0.000 description 1
- IANKQSHHNQXEEV-UHFFFAOYSA-N 5-[[4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-(trifluoromethyl)pentylidene]amino]-n-methylquinoline-2-carboxamide Chemical compound C=1C=CC2=NC(C(=O)NC)=CC=C2C=1N=CC(O)(C(F)(F)F)CC(C)(C)C1=CC(F)=CC=C1OC IANKQSHHNQXEEV-UHFFFAOYSA-N 0.000 description 1
- ZBXKAKAOXQXUOB-UHFFFAOYSA-N 5-[[4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-(trifluoromethyl)pentylidene]amino]quinoline-2-carboxamide Chemical compound COC1=CC=C(F)C=C1C(C)(C)CC(O)(C(F)(F)F)C=NC1=CC=CC2=NC(C(N)=O)=CC=C12 ZBXKAKAOXQXUOB-UHFFFAOYSA-N 0.000 description 1
- IFASTKHFFPGCII-UHFFFAOYSA-N 5-amino-n,n-diethylquinoline-2-carboxamide Chemical compound NC1=CC=CC2=NC(C(=O)N(CC)CC)=CC=C21 IFASTKHFFPGCII-UHFFFAOYSA-N 0.000 description 1
- DFHQEYWWVKMCJR-UHFFFAOYSA-N 5-amino-n-methylquinoline-2-carboxamide Chemical compound NC1=CC=CC2=NC(C(=O)NC)=CC=C21 DFHQEYWWVKMCJR-UHFFFAOYSA-N 0.000 description 1
- DTVYNUOOZIKEEX-UHFFFAOYSA-N 5-aminoisoquinoline Chemical compound N1=CC=C2C(N)=CC=CC2=C1 DTVYNUOOZIKEEX-UHFFFAOYSA-N 0.000 description 1
- APQGIAYQAYOKSU-UHFFFAOYSA-N 5-aminoquinoline-2-carboxylic acid Chemical compound OC(=O)C1=CC=C2C(N)=CC=CC2=N1 APQGIAYQAYOKSU-UHFFFAOYSA-N 0.000 description 1
- NDDZXHOCOKCNBM-UHFFFAOYSA-N 5-nitroquinoline Chemical compound C1=CC=C2C([N+](=O)[O-])=CC=CC2=N1 NDDZXHOCOKCNBM-UHFFFAOYSA-N 0.000 description 1
- QRNHAJDHLIRMED-UHFFFAOYSA-N 5-nitroquinoline-2-carbaldehyde Chemical compound O=CC1=CC=C2C([N+](=O)[O-])=CC=CC2=N1 QRNHAJDHLIRMED-UHFFFAOYSA-N 0.000 description 1
- SHPQVJNNBXMZRW-UHFFFAOYSA-N 6-butyldec-5-en-5-yltin Chemical compound CCCCC([Sn])=C(CCCC)CCCC SHPQVJNNBXMZRW-UHFFFAOYSA-N 0.000 description 1
- WDYVUKGVKRZQNM-UHFFFAOYSA-N 6-phosphonohexylphosphonic acid Chemical compound OP(O)(=O)CCCCCCP(O)(O)=O WDYVUKGVKRZQNM-UHFFFAOYSA-N 0.000 description 1
- VJCZMFDFXXYGSN-UHFFFAOYSA-N 7-bromo-1,3-benzodioxole-4-carboxylic acid Chemical compound OC(=O)C1=CC=C(Br)C2=C1OCO2 VJCZMFDFXXYGSN-UHFFFAOYSA-N 0.000 description 1
- GCGCHVGCHMDRAB-UHFFFAOYSA-N 7-nitro-1,3-benzodioxole-4-carbaldehyde Chemical compound [O-][N+](=O)C1=CC=C(C=O)C2=C1OCO2 GCGCHVGCHMDRAB-UHFFFAOYSA-N 0.000 description 1
- KHIRFDDYHRRUGO-UHFFFAOYSA-N 7-nitro-1,3-benzodioxole-4-carboxylic acid Chemical compound OC(=O)C1=CC=C([N+]([O-])=O)C2=C1OCO2 KHIRFDDYHRRUGO-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- WREVVZMUNPAPOV-UHFFFAOYSA-N 8-aminoquinoline Chemical compound C1=CN=C2C(N)=CC=CC2=C1 WREVVZMUNPAPOV-UHFFFAOYSA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000005676 Adrenogenital syndrome Diseases 0.000 description 1
- 206010057380 Allergic keratitis Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010001889 Alveolitis Diseases 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- 206010003267 Arthritis reactive Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- ODKQUWBDBJOSQT-UHFFFAOYSA-N C1=CC=C2C([N])=NC=CC2=C1 Chemical group C1=CC=C2C([N])=NC=CC2=C1 ODKQUWBDBJOSQT-UHFFFAOYSA-N 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012441 Dermatitis bullous Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 206010015218 Erythema multiforme Diseases 0.000 description 1
- 206010015226 Erythema nodosum Diseases 0.000 description 1
- GISRWBROCYNDME-PELMWDNLSA-N F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C Chemical compound F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C GISRWBROCYNDME-PELMWDNLSA-N 0.000 description 1
- 208000028387 Felty syndrome Diseases 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
- 206010021750 Infantile Spasms Diseases 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 229920006063 Lamide® Polymers 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 description 1
- 102100021316 Mineralocorticoid receptor Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 208000011623 Obstructive Lung disease Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000003435 Optic Neuritis Diseases 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229910019213 POCl3 Inorganic materials 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 201000011152 Pemphigus Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 206010036774 Proctitis Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000030934 Restrictive pulmonary disease Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 201000002015 Thyroid Crisis Diseases 0.000 description 1
- 206010043786 Thyrotoxic crisis Diseases 0.000 description 1
- 229910021627 Tin(IV) chloride Inorganic materials 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 101150046432 Tril gene Proteins 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 208000035868 Vascular inflammations Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- FLPJBZWQFYTISN-UHFFFAOYSA-N [5-[[4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-(trifluoromethyl)pentylidene]amino]quinolin-2-yl]methyl acetate Chemical compound COC1=CC=C(F)C=C1C(C)(C)CC(O)(C(F)(F)F)C=NC1=CC=CC2=NC(COC(C)=O)=CC=C12 FLPJBZWQFYTISN-UHFFFAOYSA-N 0.000 description 1
- XYLXXNFYVQYJRZ-UHFFFAOYSA-M [Cl-].[Mg+]C.C1CCOC1 Chemical compound [Cl-].[Mg+]C.C1CCOC1 XYLXXNFYVQYJRZ-UHFFFAOYSA-M 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000007825 activation reagent Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 229940111121 antirheumatic drug quinolines Drugs 0.000 description 1
- 206010003230 arteritis Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- 208000002479 balanitis Diseases 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- 208000010217 blepharitis Diseases 0.000 description 1
- 239000003914 blood derivative Substances 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229950005499 carbon tetrachloride Drugs 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 229940039231 contrast media Drugs 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- FJBFPHVGVWTDIP-UHFFFAOYSA-N dibromomethane Chemical compound BrCBr FJBFPHVGVWTDIP-UHFFFAOYSA-N 0.000 description 1
- HRLHOWWCFUKTIY-UHFFFAOYSA-L dichloroalumanylium Chemical compound Cl[Al+]Cl HRLHOWWCFUKTIY-UHFFFAOYSA-L 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- GUVUOGQBMYCBQP-UHFFFAOYSA-N dmpu Chemical compound CN1CCCN(C)C1=O GUVUOGQBMYCBQP-UHFFFAOYSA-N 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 210000000959 ear middle Anatomy 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- ZRSDQBKGDNPFLT-UHFFFAOYSA-N ethanol;oxolane Chemical compound CCO.C1CCOC1 ZRSDQBKGDNPFLT-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- VKIWONMJPOTZNB-UHFFFAOYSA-N ethyl 2-diethoxyphosphoryl-2-ethoxyacetate Chemical compound CCOC(=O)C(OCC)P(=O)(OCC)OCC VKIWONMJPOTZNB-UHFFFAOYSA-N 0.000 description 1
- OUJRZMYAWPFRSV-UHFFFAOYSA-N ethyl 2-hydroxy-4-methyl-2-(trifluoromethyl)pent-4-enoate Chemical compound CCOC(=O)C(O)(C(F)(F)F)CC(C)=C OUJRZMYAWPFRSV-UHFFFAOYSA-N 0.000 description 1
- XMBJRYWYHDCRAE-UHFFFAOYSA-N ethyl 4-(2-chloro-4-methoxyphenyl)-2-hydroxy-4-methyl-2-(trifluoromethyl)pentanoate Chemical compound CCOC(=O)C(O)(C(F)(F)F)CC(C)(C)C1=CC=C(OC)C=C1Cl XMBJRYWYHDCRAE-UHFFFAOYSA-N 0.000 description 1
- LZUANFFCVACTEG-UHFFFAOYSA-N ethyl 4-(4-chloro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-(trifluoromethyl)pentanoate Chemical compound CCOC(=O)C(O)(C(F)(F)F)CC(C)(C)C1=CC=C(Cl)C=C1OC LZUANFFCVACTEG-UHFFFAOYSA-N 0.000 description 1
- RXAGWMQCEQEFSB-UHFFFAOYSA-N ethyl 4-(7-bromo-1,3-benzodioxol-4-yl)-2-hydroxy-4-methyl-2-(trifluoromethyl)pentanoate Chemical compound CCOC(=O)C(O)(C(F)(F)F)CC(C)(C)C1=CC=C(Br)C2=C1OCO2 RXAGWMQCEQEFSB-UHFFFAOYSA-N 0.000 description 1
- NGQWNAOMXVYKON-UHFFFAOYSA-N ethyl 4-(7-bromo-1,3-benzodioxol-4-yl)-4-methyl-2-oxopentanoate Chemical class CCOC(=O)C(=O)CC(C)(C)C1=CC=C(Br)C2=C1OCO2 NGQWNAOMXVYKON-UHFFFAOYSA-N 0.000 description 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 description 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 150000004673 fluoride salts Chemical class 0.000 description 1
- 125000003784 fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- YTKZHDYSHIZVBH-UHFFFAOYSA-N heptane;oxolane;toluene Chemical compound C1CCOC1.CCCCCCC.CC1=CC=CC=C1 YTKZHDYSHIZVBH-UHFFFAOYSA-N 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 208000025036 lymphosarcoma Diseases 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- NIQQIJXGUZVEBB-UHFFFAOYSA-N methanol;propan-2-one Chemical compound OC.CC(C)=O NIQQIJXGUZVEBB-UHFFFAOYSA-N 0.000 description 1
- DOAJWTSNTNAEIY-UHFFFAOYSA-N methyl 2,3-dihydroxybenzoate Chemical compound COC(=O)C1=CC=CC(O)=C1O DOAJWTSNTNAEIY-UHFFFAOYSA-N 0.000 description 1
- MHHYSHFIEZJLKM-UHFFFAOYSA-N methyl 2-hydroxy-4-methyl-4-phenyl-2-(trifluoromethyl)pentanoate Chemical compound COC(=O)C(O)(C(F)(F)F)CC(C)(C)C1=CC=CC=C1 MHHYSHFIEZJLKM-UHFFFAOYSA-N 0.000 description 1
- CRZGFIMLHZTLGT-UHFFFAOYSA-N methyl 2-methyl-3-nitrobenzoate Chemical compound COC(=O)C1=CC=CC([N+]([O-])=O)=C1C CRZGFIMLHZTLGT-UHFFFAOYSA-N 0.000 description 1
- DVDFGBQOFICTNV-UHFFFAOYSA-N methyl 4-methyl-2-oxo-4-phenylpentanoate Chemical compound COC(=O)C(=O)CC(C)(C)C1=CC=CC=C1 DVDFGBQOFICTNV-UHFFFAOYSA-N 0.000 description 1
- STDBZEKDJRLZMW-UHFFFAOYSA-N methyl 5-[[3,3,3-trifluoro-2-[[1-(5-fluoro-2-methoxyphenyl)cyclopropyl]methyl]-2-hydroxypropylidene]amino]quinoline-2-carboxylate Chemical compound C=1C=CC2=NC(C(=O)OC)=CC=C2C=1N=CC(O)(C(F)(F)F)CC1(C=2C(=CC=C(F)C=2)OC)CC1 STDBZEKDJRLZMW-UHFFFAOYSA-N 0.000 description 1
- XVXCLDNUWBUICD-UHFFFAOYSA-N methyl 5-bromo-2-methoxybenzoate Chemical compound COC(=O)C1=CC(Br)=CC=C1OC XVXCLDNUWBUICD-UHFFFAOYSA-N 0.000 description 1
- KDIHRXOURWWATM-UHFFFAOYSA-N methyl 7-bromo-1,3-benzodioxole-4-carboxylate Chemical class COC(=O)C1=CC=C(Br)C2=C1OCO2 KDIHRXOURWWATM-UHFFFAOYSA-N 0.000 description 1
- HXVOLPKNEJWEJM-UHFFFAOYSA-N methyl 8-aminoquinoline-2-carboxylate Chemical compound C1=CC=C(N)C2=NC(C(=O)OC)=CC=C21 HXVOLPKNEJWEJM-UHFFFAOYSA-N 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N monoethanolamine hydrochloride Natural products NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- JQNGUBDEHJXCHA-UHFFFAOYSA-N n-(2-methylquinolin-5-yl)acetamide Chemical compound CC1=CC=C2C(NC(=O)C)=CC=CC2=N1 JQNGUBDEHJXCHA-UHFFFAOYSA-N 0.000 description 1
- NQJNITDATGCFNE-UHFFFAOYSA-N n-[1-(7-bromo-1,3-benzodioxol-4-yl)-2-hydroxy-4-methyl-2-(trifluoromethyl)pentyl]-n-(2-methylquinolin-5-yl)acetamide Chemical compound C=1C=CC2=NC(C)=CC=C2C=1N(C(C)=O)C(C(O)(CC(C)C)C(F)(F)F)C1=CC=C(Br)C2=C1OCO2 NQJNITDATGCFNE-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- DCUAMTJWBANOQC-UHFFFAOYSA-N n-methyl-5-nitroquinolin-2-amine Chemical compound [O-][N+](=O)C1=CC=CC2=NC(NC)=CC=C21 DCUAMTJWBANOQC-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 208000028931 non-acquired combined pituitary hormone deficiency Diseases 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012285 osmium tetroxide Substances 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 229960003540 oxyquinoline Drugs 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 210000003695 paranasal sinus Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 201000001976 pemphigus vulgaris Diseases 0.000 description 1
- 208000000689 peptic esophagitis Diseases 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000005506 phthalide group Chemical group 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 206010035116 pityriasis rubra pilaris Diseases 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 201000006292 polyarteritis nodosa Diseases 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 235000021395 porridge Nutrition 0.000 description 1
- 230000018656 positive regulation of gluconeogenesis Effects 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 108020003113 steroid hormone receptors Proteins 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 201000007497 subacute thyroiditis Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 1
- 125000006337 tetrafluoro ethyl group Chemical group 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- HPINPCFOKNNWNW-UHFFFAOYSA-N thiete Chemical compound C1SC=C1 HPINPCFOKNNWNW-UHFFFAOYSA-N 0.000 description 1
- GZNAASVAJNXPPW-UHFFFAOYSA-M tin(4+) chloride dihydrate Chemical compound O.O.[Cl-].[Sn+4] GZNAASVAJNXPPW-UHFFFAOYSA-M 0.000 description 1
- FWPIDFUJEMBDLS-UHFFFAOYSA-L tin(II) chloride dihydrate Substances O.O.Cl[Sn]Cl FWPIDFUJEMBDLS-UHFFFAOYSA-L 0.000 description 1
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 1
- JOQGJRQKCIJIDB-UHFFFAOYSA-M tin;chloride Chemical compound [Cl-].[Sn] JOQGJRQKCIJIDB-UHFFFAOYSA-M 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 208000002003 vulvitis Diseases 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/40—Nitrogen atoms attached in position 8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10215316A DE10215316C1 (de) | 2002-04-02 | 2002-04-02 | Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer |
| PCT/EP2003/003298 WO2003082827A1 (de) | 2002-04-02 | 2003-03-29 | Chinolin- und isochinolin-derivate, ein verfahren zu ihrer herstellung und ihre verwendung als entzündungshemmer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20044731L NO20044731L (no) | 2004-12-30 |
| NO329668B1 true NO329668B1 (no) | 2010-11-29 |
Family
ID=28458623
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20044731A NO329668B1 (no) | 2002-04-02 | 2004-11-01 | Kinolin- og isokinolinderivater, farmasoytiske preparater som inneholder minst en slik forbindelse, fremgangsmate for frmstilling av forbindelsene og anvendelse derav for fremstilling av farmasoytiske midler |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US7329753B2 (ru) |
| EP (1) | EP1492771B1 (ru) |
| JP (1) | JP4593929B2 (ru) |
| KR (1) | KR100967277B1 (ru) |
| CN (1) | CN1659144B (ru) |
| AR (1) | AR039222A1 (ru) |
| AT (1) | ATE355277T1 (ru) |
| AU (1) | AU2003215678B2 (ru) |
| BR (1) | BR0308967A (ru) |
| CA (1) | CA2481012C (ru) |
| CY (1) | CY1106598T1 (ru) |
| DE (2) | DE10215316C1 (ru) |
| DK (1) | DK1492771T3 (ru) |
| EA (1) | EA008540B1 (ru) |
| EC (1) | ECSP045399A (ru) |
| ES (1) | ES2282649T3 (ru) |
| HK (1) | HK1081193A1 (ru) |
| HR (1) | HRP20041005B1 (ru) |
| IL (1) | IL164292A (ru) |
| ME (2) | MEP14208A (ru) |
| MX (1) | MXPA04009684A (ru) |
| NO (1) | NO329668B1 (ru) |
| NZ (1) | NZ535872A (ru) |
| PE (1) | PE20040081A1 (ru) |
| PL (1) | PL212322B1 (ru) |
| PT (1) | PT1492771E (ru) |
| RS (1) | RS50931B (ru) |
| SI (1) | SI1492771T1 (ru) |
| TW (1) | TWI272267B (ru) |
| UA (1) | UA78304C2 (ru) |
| UY (1) | UY27748A1 (ru) |
| WO (1) | WO2003082827A1 (ru) |
| ZA (1) | ZA200408827B (ru) |
Families Citing this family (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10346940B3 (de) * | 2003-10-06 | 2005-06-16 | Schering Ag | Substituierte Pentanole, ihre Verwendung zur Herstellung von Arzneimitteln speziell Entzündungshemmer sowie diese enthaltende pharmazeutische Präparate |
| US7238707B2 (en) | 2000-07-28 | 2007-07-03 | Schering Ag | Substituted pentanols, a process for their production and their use as anti-inflammatory agents |
| CN1633296A (zh) | 2002-03-26 | 2005-06-29 | 贝林格尔·英格海姆药物公司 | 糖皮质素模拟物、其制备方法、药物组合物及其用途 |
| TWI328009B (en) | 2003-05-21 | 2010-08-01 | Glaxo Group Ltd | Quinoline derivatives as phosphodiesterase inhibitors |
| JP2008529963A (ja) * | 2003-07-01 | 2008-08-07 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | 複素環式−置換されたペンタノール誘導体類、それらの生成方法及び抗炎症剤としてのそれらの使用 |
| GB0316290D0 (en) | 2003-07-11 | 2003-08-13 | Glaxo Group Ltd | Novel compounds |
| UY28526A1 (es) | 2003-09-24 | 2005-04-29 | Boehringer Ingelheim Pharma | Miméticos de glucocorticoides, métodos de preparación composiciones farmacéuticas y usos de los mismos |
| US7662821B2 (en) | 2003-10-08 | 2010-02-16 | Bayer Schering Pharma Ag | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents |
| US7638515B2 (en) | 2003-10-08 | 2009-12-29 | Bayer Schering Pharma Aktiengesellschaft | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents |
| PT1670458E (pt) | 2003-10-08 | 2007-03-30 | Schering Ag | Derivados de tetra-hidronaftaleno, processo para a sua preparação e utilização como inibidor de inflamação |
| JP4468369B2 (ja) * | 2003-10-16 | 2010-05-26 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | ある種のトリフルオロメチル置換アルコールの立体選択的合成 |
| US7795272B2 (en) | 2004-03-13 | 2010-09-14 | Boehringer Ingelheim Pharmaceutical, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof |
| US20080153859A1 (en) | 2004-04-05 | 2008-06-26 | Hartmut Rehwinkel | Multiply-substituted tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents |
| AR049384A1 (es) | 2004-05-24 | 2006-07-26 | Glaxo Group Ltd | Derivados de purina |
| TWI307630B (en) | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
| GB0418045D0 (en) | 2004-08-12 | 2004-09-15 | Glaxo Group Ltd | Compounds |
| DE102004044680B3 (de) * | 2004-09-09 | 2006-06-08 | Schering Ag | Alkyliden-Tetrahydronaphthalinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer sowie diese enthaltende pharmazeutische Präparate |
| US7417056B2 (en) | 2004-11-12 | 2008-08-26 | Schering Ag | 5-substituted quinoline and isoquinoline derivatives, a process for their production and their use as anti-inflammatory agents |
| DE102005020331A1 (de) * | 2005-04-26 | 2006-11-02 | Schering Ag | 5-substituierte Chinolin- und Isochinolin-Derivate, ein Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer |
| DE102004055633A1 (de) * | 2004-11-12 | 2006-05-18 | Schering Ag | 5-substituierte Chinolin- und Isochinolin-Derivate, ein Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer |
| DE102004063227A1 (de) * | 2004-12-22 | 2006-07-06 | Schering Ag | Tricylische Aminoalkohole, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer |
| ES2326907T3 (es) | 2004-12-27 | 2009-10-21 | Boehringer Ingelheim Pharmaceuticals Inc. | Mimeticos de glucocorticoides, metodos para su preparacion, composiciones farmaceuticas y su uso. |
| US7579335B2 (en) | 2005-01-10 | 2009-08-25 | Glaxo Group Limited | Androstane 17α-carbonate derivatives for use in the treatment of allergic and inflammatory conditions |
| US7402596B2 (en) | 2005-03-24 | 2008-07-22 | Renovis, Inc. | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof |
| AR053450A1 (es) | 2005-03-25 | 2007-05-09 | Glaxo Group Ltd | Derivados de 3,4-dihidro-pirimido(4,5-d)pirimidin-2-(1h)-ona 1,5,7 trisustituidos como inhibidores de la quinasa p38 |
| MY145281A (en) | 2005-03-25 | 2012-01-13 | Glaxo Group Ltd | Novel compounds |
| DE102005018025A1 (de) * | 2005-04-14 | 2006-11-02 | Schering Ag | Mehrfach substituierte bizyklische Systeme, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer |
| DE102005018026B4 (de) * | 2005-04-14 | 2006-12-21 | Schering Ag | Substituierte Styrole, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer |
| DE102005017301A1 (de) * | 2005-04-14 | 2006-10-19 | Schering Ag | Substituierte Chromanderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer |
| GB0514809D0 (en) | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
| AR058109A1 (es) | 2005-12-20 | 2008-01-23 | Glaxo Group Ltd | Acido 3 - (4 - {[4 -(4 -{[3 - (3, 3 - dimetil - 1 - piperidinil)propil]oxi}fenil) - 1 - piperidinil]carbonil} - 1 - naftalenil)propanoico como antagonistas de los receptotres de histamina h1/h3, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamie |
| EP1834948A1 (de) | 2006-03-15 | 2007-09-19 | Bayer Schering Pharma Aktiengesellschaft | Tetrahydronaphthalinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer |
| TWI464148B (zh) | 2006-03-16 | 2014-12-11 | Evotec Us Inc | 作為ｐ２ｘ7調節劑之雙環雜芳基化合物與其用途 |
| CA2649509A1 (en) | 2006-04-20 | 2007-11-01 | Glaxo Group Limited | Novel compounds |
| GB0611587D0 (en) | 2006-06-12 | 2006-07-19 | Glaxo Group Ltd | Novel compounds |
| AU2007319590A1 (en) * | 2006-11-09 | 2008-05-22 | Bausch & Lomb Incorporated | Synthesis of selected stereoisomers of certain substituted alcohols |
| WO2008070507A2 (en) | 2006-12-06 | 2008-06-12 | Boehringer Ingelheim International Gmbh | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| US20080171873A1 (en) * | 2007-01-12 | 2008-07-17 | Harms Arthur E | Synthesis of selected stereoisomers of certain substituted alcohols |
| EP2124562B1 (en) | 2007-03-09 | 2016-04-20 | Second Genome, Inc. | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof |
| PE20081889A1 (es) | 2007-03-23 | 2009-03-05 | Smithkline Beecham Corp | Indol carboxamidas como inhibidores de ikk2 |
| EP2016935A1 (en) * | 2007-07-09 | 2009-01-21 | Intendis GmbH | Pharmaceutical composition for topical application of poorly soluble compounds |
| MX2010012814A (es) | 2008-05-23 | 2010-12-20 | Amira Pharmaceuticals Inc | Inhibidor de proteina activadora de 5-lipoxigenasa. |
| EP2280959B1 (en) | 2008-06-05 | 2012-04-04 | Glaxo Group Limited | 4-amino-indazoles |
| WO2009147187A1 (en) | 2008-06-05 | 2009-12-10 | Glaxo Group Limited | 4-carboxamide indazole derivatives useful as inhibitors of p13-kinases |
| MX2010013095A (es) | 2008-06-06 | 2010-12-21 | Boehringer Ingelheim Int | Mimeticos de glucocorticoides, metodos para su fabricacion, composiciones farmaceuticas y usos de los mismos. |
| WO2010094643A1 (en) | 2009-02-17 | 2010-08-26 | Glaxo Group Limited | Quinoline derivatives and their uses for rhinitis and urticaria |
| JP5656880B2 (ja) | 2009-03-09 | 2015-01-21 | グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ | Ｐｉ３キナーゼの阻害剤としての４−オキサジアゾール−２−イル−インダゾール |
| JP2012520257A (ja) | 2009-03-10 | 2012-09-06 | グラクソ グループ リミテッド | Ｉｋｋ２阻害剤としてのインドール誘導体 |
| WO2010106016A1 (en) | 2009-03-17 | 2010-09-23 | Glaxo Group Limited | Pyrimidine derivatives used as itk inhibitors |
| WO2010107958A1 (en) | 2009-03-19 | 2010-09-23 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| JP2012520683A (ja) | 2009-03-19 | 2012-09-10 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸（ｓｉＮＡ）を用いた結合組織増殖因子（ＣＴＧＦ）遺伝子発現のＲＮＡ干渉媒介性阻害 |
| EP2408915A2 (en) | 2009-03-19 | 2012-01-25 | Merck Sharp&Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GATA BINDING PROTEIN 3 (GATA3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| JP2012520684A (ja) | 2009-03-19 | 2012-09-10 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸（ｓｉＮＡ）を用いたＢＴＢａｎｄＣＮＣＨｏｍｏｌｏｇｙ１（塩基性ロイシンジッパー転写因子１）（Ｂａｃｈ１）遺伝子発現のＲＮＡ干渉媒介性阻害 |
| US20120004281A1 (en) | 2009-03-27 | 2012-01-05 | Merck Sharp & Dohme Corp | RNA Interference Mediated Inhibition of the Nerve Growth Factor Beta Chain (NGFB) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
| CA2756069A1 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | Rna interference mediated inhibition of the intercellular adhesion molecule 1 (icam-1)gene expression using short interfering nucleic acid (sina) |
| US20120022143A1 (en) | 2009-03-27 | 2012-01-26 | Merck Sharp & Dohme Corp | RNA Interference Mediated Inhibition of the Thymic Stromal Lymphopoietin (TSLP) Gene Expression Using Short Interfering Nucliec Acid (siNA) |
| EP2411516A1 (en) | 2009-03-27 | 2012-02-01 | Merck Sharp&Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| WO2010111471A2 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| EP2421834A1 (en) | 2009-04-24 | 2012-02-29 | Glaxo Group Limited | Pyrazole and triazole carboxamides as crac channel inhibitors |
| US8399436B2 (en) | 2009-04-24 | 2013-03-19 | Glaxo Group Limited | N-pyrazolyl carboxamides as CRAC channel inhibitors |
| PL2899191T3 (pl) | 2009-04-30 | 2018-01-31 | Glaxo Group Ltd | Indazole podstawione oksazolem jako inhibitory kinazy PI3 |
| AU2010280323A1 (en) | 2009-07-31 | 2012-03-08 | Cadila Healthcare Limited | Novel compounds as modulators of glucocorticoid receptors |
| EP2507231A1 (en) | 2009-12-03 | 2012-10-10 | Glaxo Group Limited | Indazole derivatives as pi 3 - kinase inhibitors |
| WO2011067365A1 (en) | 2009-12-03 | 2011-06-09 | Glaxo Group Limited | Benzpyrazole derivatives as inhibitors of p13 kinases |
| US20120238559A1 (en) | 2009-12-03 | 2012-09-20 | Glaxo Group Limited | Novel compounds |
| EP3020393B1 (en) | 2009-12-16 | 2020-10-07 | 3M Innovative Properties Company | Formulations and methods for controlling mdi particle size delivery |
| WO2011110575A1 (en) | 2010-03-11 | 2011-09-15 | Glaxo Group Limited | Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases |
| GB201007203D0 (en) | 2010-04-29 | 2010-06-16 | Glaxo Group Ltd | Novel compounds |
| PL2614058T3 (pl) | 2010-09-08 | 2015-12-31 | Glaxosmithkline Ip Dev Ltd | Polimorfy i sole n-[5-[4-(5-{[(2r,6s)-2,6-dimetylo-4-morfolinylo]-metylo}-1,3-oksazol-2-ilo)-1h-indazol-6-ilo]-2-(metyloksy)-3-pirydynylo]metanosulfonamidu |
| EP2613781B1 (en) | 2010-09-08 | 2016-08-24 | GlaxoSmithKline Intellectual Property Development Limited | Indazole derivatives for use in the treatment of influenza virus infection |
| WO2012035055A1 (en) | 2010-09-17 | 2012-03-22 | Glaxo Group Limited | Novel compounds |
| ES2532213T3 (es) | 2010-10-21 | 2015-03-25 | Glaxo Group Limited | Compuestos de pirazol que actúan contra afecciones alérgicas, inmunitarias e inflamatorias |
| JP2013544794A (ja) | 2010-10-21 | 2013-12-19 | グラクソ グループ リミテッド | アレルギー性障害、炎症性障害及び免疫障害に作用するピラゾール化合物 |
| GB201018124D0 (en) | 2010-10-27 | 2010-12-08 | Glaxo Group Ltd | Polymorphs and salts |
| JP2014507458A (ja) | 2011-03-11 | 2014-03-27 | グラクソ グループ リミテッド | Ｓｙｋインヒビターとしてのピリド［３，４−Ｂ］ピラジン誘導体 |
| GB201104153D0 (en) | 2011-03-11 | 2011-04-27 | Glaxo Group Ltd | Novel compounds |
| SG11201600707QA (en) | 2013-09-22 | 2016-02-26 | Calitor Sciences Llc | Substituted aminopyrimidine compounds and methods of use |
| CA2925064A1 (en) | 2013-10-17 | 2015-04-23 | Glaxosmithkline Intellectual Property Development Limited | Pi3k inhibitor for treatment of respiratory disease |
| JP2016537327A (ja) | 2013-10-17 | 2016-12-01 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | 呼吸器疾患の治療のためのｐｉ３ｋ阻害剤 |
| JP6517319B2 (ja) | 2014-03-28 | 2019-05-22 | キャリター・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＣａｌｉｔｏｒ Ｓｃｉｅｎｃｅｓ， Ｌｌｃ | 置換されたヘテロアリール化合物および使用方法 |
| EA201692111A1 (ru) | 2014-05-12 | 2017-08-31 | Глаксосмитклайн Интеллекчуал Проперти (№ 2) Лимитед | Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний |
| WO2017044434A1 (en) | 2015-09-11 | 2017-03-16 | Sunshine Lake Pharma Co., Ltd. | Substituted heteroaryl compounds and methods of use |
| GB201602527D0 (en) | 2016-02-12 | 2016-03-30 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
| EP3497100A1 (en) | 2016-08-08 | 2019-06-19 | GlaxoSmithKline Intellectual Property Development Limited | Chemical compounds |
| GB201706102D0 (en) | 2017-04-18 | 2017-05-31 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
| GB201712081D0 (en) | 2017-07-27 | 2017-09-13 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
| EP3710006A4 (en) | 2017-11-19 | 2021-09-01 | Sunshine Lake Pharma Co., Ltd. | SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR METHODS OF USE |
| US10751339B2 (en) | 2018-01-20 | 2020-08-25 | Sunshine Lake Pharma Co., Ltd. | Substituted aminopyrimidine compounds and methods of use |
| EP4125919A1 (en) | 2020-03-26 | 2023-02-08 | GlaxoSmithKline Intellectual Property Development Limited | Cathepsin inhibitors for preventing or treating viral infections |
| CN113480512B (zh) * | 2021-07-23 | 2022-07-29 | 阜阳欣奕华制药科技有限公司 | 一种1-(7-溴苯并并[d][1,3]二氧杂环戊烯-4-基)乙-1-酮的制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8617653D0 (en) * | 1986-07-18 | 1986-08-28 | Ici Plc | Amide derivatives |
| DE19723722A1 (de) * | 1997-05-30 | 1998-12-10 | Schering Ag | Nichtsteroidale Gestagene |
| DE19856475A1 (de) * | 1998-11-27 | 2000-05-31 | Schering Ag | Nichtsteroidale Entzündungshemmer |
| DE10038639A1 (de) * | 2000-07-28 | 2002-02-21 | Schering Ag | Nichtsteroidale Entzündungshemmer |
| US6897224B2 (en) * | 2002-04-02 | 2005-05-24 | Schering Ag | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors |
-
2002
- 2002-04-02 DE DE10215316A patent/DE10215316C1/de not_active Expired - Lifetime
-
2003
- 2003-03-29 ME MEP-142/08A patent/MEP14208A/xx unknown
- 2003-03-29 EP EP03745195A patent/EP1492771B1/de not_active Expired - Lifetime
- 2003-03-29 WO PCT/EP2003/003298 patent/WO2003082827A1/de active IP Right Grant
- 2003-03-29 PT PT03745195T patent/PT1492771E/pt unknown
- 2003-03-29 AU AU2003215678A patent/AU2003215678B2/en not_active Ceased
- 2003-03-29 AT AT03745195T patent/ATE355277T1/de active
- 2003-03-29 DE DE50306659T patent/DE50306659D1/de not_active Expired - Lifetime
- 2003-03-29 SI SI200330748T patent/SI1492771T1/sl unknown
- 2003-03-29 BR BR0308967-3A patent/BR0308967A/pt not_active IP Right Cessation
- 2003-03-29 CA CA2481012A patent/CA2481012C/en not_active Expired - Fee Related
- 2003-03-29 PL PL372884A patent/PL212322B1/pl unknown
- 2003-03-29 ME MEP-2008-142A patent/ME00159B/me unknown
- 2003-03-29 ES ES03745195T patent/ES2282649T3/es not_active Expired - Lifetime
- 2003-03-29 KR KR1020047015697A patent/KR100967277B1/ko not_active IP Right Cessation
- 2003-03-29 NZ NZ535872A patent/NZ535872A/en not_active IP Right Cessation
- 2003-03-29 DK DK03745195T patent/DK1492771T3/da active
- 2003-03-29 CN CN038126842A patent/CN1659144B/zh not_active Expired - Fee Related
- 2003-03-29 EA EA200401294A patent/EA008540B1/ru not_active IP Right Cessation
- 2003-03-29 MX MXPA04009684A patent/MXPA04009684A/es active IP Right Grant
- 2003-03-29 RS YUP-868/04A patent/RS50931B/sr unknown
- 2003-03-29 UA UA20041108938A patent/UA78304C2/uk unknown
- 2003-03-29 JP JP2003580295A patent/JP4593929B2/ja not_active Expired - Fee Related
- 2003-04-02 UY UY27748A patent/UY27748A1/es not_active Application Discontinuation
- 2003-04-02 TW TW092107522A patent/TWI272267B/zh not_active IP Right Cessation
- 2003-04-02 PE PE2003000334A patent/PE20040081A1/es not_active Application Discontinuation
- 2003-04-02 AR ARP030101145A patent/AR039222A1/es active IP Right Grant
-
2004
- 2004-09-27 IL IL164292A patent/IL164292A/en not_active IP Right Cessation
- 2004-10-26 HR HRP20041005AA patent/HRP20041005B1/hr not_active IP Right Cessation
- 2004-10-29 EC EC2004005399A patent/ECSP045399A/es unknown
- 2004-11-01 NO NO20044731A patent/NO329668B1/no not_active IP Right Cessation
- 2004-11-01 ZA ZA200408827A patent/ZA200408827B/xx unknown
-
2006
- 2006-01-27 HK HK06101274.9A patent/HK1081193A1/xx not_active IP Right Cessation
- 2006-06-13 US US11/451,508 patent/US7329753B2/en not_active Expired - Fee Related
-
2007
- 2007-05-17 CY CY20071100665T patent/CY1106598T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO329668B1 (no) | Kinolin- og isokinolinderivater, farmasoytiske preparater som inneholder minst en slik forbindelse, fremgangsmate for frmstilling av forbindelsene og anvendelse derav for fremstilling av farmasoytiske midler | |
| US6897224B2 (en) | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors | |
| US7442794B2 (en) | Rearranged pentanols, a process for their production and their use as anti-inflammatory agents | |
| CA2531060A1 (en) | Heterocyclically-substitued pentanol derivatives, process for their production and their use as anti-inflammatory agents | |
| KR20070089948A (ko) | 트리시클릭 아미노 알콜, 이의 합성 방법 및 항염증약물로서의 이의 용도 | |
| US20050090559A1 (en) | Heterocyclically-substituted pentanol derivatives, process for their production and their use as anti-inflammatory agents | |
| AU2007271920A1 (en) | Benzyl amines, a process for their production and their use as anti-inflammatory agents | |
| US8097627B2 (en) | Multiply-substituted tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents | |
| US20060167025A1 (en) | Tricyclic amino alcohols, processes for synthesis of same and use of same as anti-inflammatory drugs | |
| US20060084652A1 (en) | Alkylidene-tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents | |
| US20050222154A1 (en) | Multiply-substituted tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents | |
| US20050267202A1 (en) | Chromanol derivatives, a process for their production and their use as anti-inflammatory agents | |
| DE10346939A1 (de) | Heterocyclisch substituierte Pentanole, ein Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: BAYER INTELLECTUAL PROPERTY GMBH, DE |
|
| MM1K | Lapsed by not paying the annual fees |